Company intelligence / Profile preview

Atopix Therapeutics

Oxford, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Atopix Therapeutics developed oral CRTH2 antagonists for allergic and eosinophilic diseases, with its lead candidate timapiprant showing efficacy in asthma and allergic rhinoconjunctivitis in over 800 patients and demonstrating an excellent safety profile. The company focused on Th2-mediated eosinophilic asthma, targeting the CRTH2 receptor to interfere with allergic inflammation without broad immunosuppression.

Therapeutic areas: ImmunologyInfectious DiseasesDermatologyPulmonology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Atopix Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atopix Therapeutics.

Explore the full profile